Treatment of ARS deficiencies with specific amino acids

Gautam Kok, Laura Tseng, Imre F. Schene, Monique E. Dijsselhof, Gajja Salomons, Marisa I. Mendes, Desiree E. C. Smith, Arnaud Wiedemann, Marie Canton, François Feillet, Tom J. de Koning, Megan Boothe, Joy Dean, Rachel Kassel, Elise A. Ferreira, Margreet van den Born, Edward E. S. Nieuwenhuis, Holger Rehmann, Suzanne W. J. Terheggen-Lagro, Clara D. M. van Karnebeek*Sabine A. Fuchs*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review


Purpose: Recessive cytosolic aminoacyl-tRNA synthetase (ARS) deficiencies are severe multiorgan diseases, with limited treatment options. By loading transfer RNAs (tRNAs) with their cognate amino acids, ARS are essential for protein translation. However, it remains unknown why ARS deficiencies lead to specific symptoms, especially early life and during infections. We set out to increase pathophysiological insight and improve therapeutic possibilities. Methods: In fibroblasts from patients with isoleucyl-RS (IARS), leucyl-RS (LARS), phenylalanyl-RS-beta-subunit (FARSB), and seryl-RS (SARS) deficiencies, we investigated aminoacylation activity, thermostability, and sensitivity to ARS-specific amino acid concentrations, and developed personalized treatments. Results: Aminoacylation activity was reduced in all patients, and further diminished at 38.5/40 °C (PLARS and PFARSB), consistent with infectious deteriorations. With lower cognate amino acid concentrations, patient fibroblast growth was severely affected. To prevent local and/or temporal deficiencies, we treated patients with corresponding amino acids (follow-up: 1/2–2 2/3rd years), and intensified treatment during infections. All patients showed beneficial treatment effects, most strikingly in growth (without tube feeding), head circumference, development, coping with infections, and oxygen dependency. Conclusion: For these four ARS deficiencies, we observed a common disease mechanism of episodic insufficient aminoacylation to meet translational demands and illustrate the power of amino acid supplementation for the expanding ARS patient group. Moreover, we provide a strategy for personalized preclinical functional evaluation.
Original languageEnglish
Pages (from-to)2202-2207
JournalGenetics in Medicine
Issue number11
Publication statusPublished - 1 Nov 2021

Cite this